InMed Pharmaceuticals (INM)
(Delayed Data from NSDQ)
$0.27 USD
-0.02 (-6.41%)
Updated Jul 29, 2024 03:59 PM ET
After-Market: $0.27 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
INM 0.27 -0.02(-6.41%)
Will INM be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for INM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for INM
Biotech Stock Roundup: CTMX Surges on REGN's Deal, APLS Up on Regulatory Update
InMed (INM) Gets Grant to Begin Neurodegenerative Diseases Program
INM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for INM
7 F-Rated Growth Stocks to Avoid Right Now: June 2024
InMed Pharmaceuticals to Showcase at Growth Conference
Why G-III Apparel Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Why Smartsheet Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday